Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea: A Pilot Trial
Brigham and Women's Hospital
Summary
A single arm, pilot study among individuals with rosacea and at least moderate flushing or rednesss will be enrolled in a 4-week trial of taVNS. The particicpants will be followed for an additional 4-weeks following the intervention period to evaluate the durability of the results
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Adults aged 18 years of age and older * Dermatologist confirmed diagnosis of rosacea * Clinician's Erythema Assessment of at least 3 (moderate to severe disease) * Willingness to adhere to current rosacea regimen without additions or laser treatments (e.g. PDL) during the study period. Exclusion Criteria: * Changes to rosacea regimen (prescription topical or oral medications) within 4 weeks of randomization. * Facial hair, tattoos, or other characteristics that would interfere with erythema assessments * History of symptomatic cardiac arrythmias (e.g. heart block, sick…
Interventions
- DeviceTransaricular vagus nerve stimulation (taVNS)
This project consists of a 4-week trial of transaricular vagus nerve stimulation (taVNS) for rosacea. Participation is expected to last for a total duration of 8 weeks (4 week active intervention period)
Location
- Brigham and Women's HospitalBoston, Massachusetts